Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
TAT 2015 Congress: co-organised by Gustave Roussy
Co-organised by Gustave Roussy, the 13rd TAT Congress took place in Paris from the 2nd to the 4th of March. Presided over this year by Prof. Jean-Charles Soria, Head of the Drug Development Department (DITEP) at Gustave Roussy, the TAT congress is the first International Meeting on the early development of medicines in oncology.
Published on
Changed on
Co-organised by Gustave Roussy, the 13rd TAT Congress took place in Paris from the 2nd to the 4th of March. Presided over this year by Prof. Jean-Charles Soria, Head of the Drug Development Department (DITEP) at Gustave Roussy, the TAT congress is the first International Meeting on the early development of medicines in oncology.
Investigators and biotechnology companies had the unique opportunity of meeting and exchanging information with worldwide experts in early clinical research, on new therapeutic targets and on innovative therapies in oncology.
In this years’ programme, a wide range of therapeutic advances was presented during 11 plenary sessions, notably by the investigating physicians from Gustave Roussy, in the forefront of thematics in the field of oncology such as immunotherapy, epigenetics or tumour metabolism.
Notable in this programme is the presentation by Dr. Christophe Massard, a medical oncologist at Gustave Roussy, on the updated results of the MOSCATO trial (MOlecular Screening for Cancer Treatment Optimization). The recent introduction of complete genome sequencing (WES) and of RNA (RNA seq) has yielded interesting preliminary results. This trial, promoted by Gustave Roussy, aims to validate in clinical practice the implementation of high flow analytical techniques in order to obtain the molecular description of the tumour of each patient and thus to refer them for the most suitable targeted therapies in order to validate the concept of “personalised medicine”.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
